                                                    Concept  PeriodEnd                                                                                                                                                              Dims        Value
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                         abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US 1.520200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                         abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US 1.008600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                         abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US 6.753000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.360000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.632000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.010000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 1.756200e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 1.171800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 7.763000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                          abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US 5.940000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                          abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US 4.259000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US 2.824000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                 abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.364000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                 abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.712000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.145000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 8.304000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 5.971000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 3.969000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                          abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US 3.062000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                          abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US 7.142000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US 1.216000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                 abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.478000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                 abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.851000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.244000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 4.540000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 8.993000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 1.440400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US 3.612000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US 3.260000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US 2.755000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 3.621000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 3.267000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 2.759000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US 3.151000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US 2.718000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US 2.476000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31     abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 6.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31     abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 5.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31     abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 5.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 3.769000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 3.283000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 2.991000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US 1.239000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US 9.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US 8.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 1.271000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 1.006000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 8.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US 9.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US 6.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US 4.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 1.036000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 6.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 4.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:country:US 1.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:country:US 1.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31               abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31               abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 9.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31               abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                  abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember 4.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                  abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember 9.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                  abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VyalevMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US 7.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US 9.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US 9.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 3.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 4.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 4.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31             abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US 1.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31             abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US 2.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31             abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US 2.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31    abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31    abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31    abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                         abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US 2.048000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                         abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US 2.448000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                         abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US 2.665000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 2.869000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 3.347000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 3.596000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                         abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US 1.306000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                         abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US 1.234000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                         abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US 1.087000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.486000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.349000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.201000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 2.792000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 2.583000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 2.288000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                           abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US 6.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                           abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US 4.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                  abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 8.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                  abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember 6.900000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember 4.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                  abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 9.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                  abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                  abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 2.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 1.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                     abbv:KeyProductPortfolioAxis:abbv:OncologyMember; srt:ProductOrServiceAxis:abbv:OtherOncologyMember; srt:StatementGeographicalAxis:country:US 3.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                   abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US 1.504000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US 1.682000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US 1.670000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31          abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.098000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.038000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.012000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 2.602000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 2.720000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 2.682000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US 3.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US 4.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US 5.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31     abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 6.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31     abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 7.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31     abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 8.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 9.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 1.177000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 1.378000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                 abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US 1.101000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                 abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US 1.118000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US 1.060000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                           abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.265000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                           abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.279000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                           abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.234000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                            abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US 1.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                            abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                            abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US 1.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                   abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                      abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 4.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                      abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 4.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                      abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                     abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US 1.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                     abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US 1.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                     abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US 1.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31            abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31            abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31            abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 2.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                               abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 4.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                               abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 4.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                               abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 4.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                   abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US 5.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US 9.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US 1.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31          abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 1.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 1.970000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 2.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 2.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                       abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US 5.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US 6.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US 8.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31              abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 4.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 4.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 4.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 1.009000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 1.071000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 1.239000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                   abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US 6.350000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US 5.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US 6.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31          abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 6.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 7.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 7.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 1.317000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 1.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 1.430000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                     abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US 1.512000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                     abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US 1.383000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                     abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US 1.268000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31          abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US 8.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US 9.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US 1.073000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31 abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 4.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31 abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31 abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                    abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 9.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                    abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 9.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                    abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 1.108000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 2.627000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 3.032000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 3.035000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:US 4.660300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:US 4.302900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:US 4.188300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:DE 1.738000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:DE 1.465000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:DE 1.266000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:JP 1.274000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:JP 1.122000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:JP 1.008000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CA 1.222000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CA 1.088000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CA 1.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CN 1.006000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CN 9.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CN 9.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:FR 8.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:FR 7.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:FR 7.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:GB 6.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:GB 5.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:GB 4.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:ES 6.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:ES 5.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:ES 5.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:IT 5.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:IT 5.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:IT 4.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:BR 4.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:BR 4.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:BR 4.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                          srt:StatementGeographicalAxis:country:AU 4.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:AU 4.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:AU 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                           srt:StatementGeographicalAxis:abbv:OtherCountriesMember 5.759000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                           srt:StatementGeographicalAxis:abbv:OtherCountriesMember 5.449000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                           srt:StatementGeographicalAxis:abbv:OtherCountriesMember 5.042000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31                                                                                                                                                                   6.116000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                   5.633400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                   5.431800e+10
                                           us-gaap:Revenues 2025-12-31                                                                                                                                                                   6.116000e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                   5.633400e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                   5.431800e+10
                                           us-gaap:Revenues 2025-12-31                                                                                                                                                                   6.116000e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                   5.633400e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                   5.431800e+10
                                           us-gaap:Revenues 2025-12-31                                                                                                                                                                   1.661800e+10
                                us-gaap:OperatingIncomeLoss 2025-12-31                                                                                                                                                                   1.507500e+10
                                us-gaap:OperatingIncomeLoss 2024-12-31                                                                                                                                                                   9.137000e+09
                                us-gaap:OperatingIncomeLoss 2023-12-31                                                                                                                                                                   1.275700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.085000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.778000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.084700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 6.774000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 6.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.709000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.166000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.708000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.205000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.255600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.940000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.559000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.170000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.231000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.912000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 6.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.699000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.225000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.184000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.614000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.930000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.137000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 6.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.765000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.165000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.165000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.896000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.896000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.129000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.129000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.415000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.415000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 9.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.227000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.294000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.294000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.592000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.338000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.599000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.343000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.323000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.988000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.779000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.410000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 6.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 6.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 6.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                        srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                        srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.830000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 5.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.579000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.823000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 7.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 8.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.198000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.499000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.410000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 9.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 9.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.850000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.108000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.007000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 7.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.082000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.928000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 4.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                  srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                  srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 5.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 5.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 4.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.900000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                     srt:ProductOrServiceAxis:abbv:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                     srt:ProductOrServiceAxis:abbv:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.084000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.253000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 8.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 7.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 6.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 6.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.885000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.033000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 9.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 5.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 7.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 8.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 8.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 8.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 9.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 9.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 9.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 8.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 8.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 9.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 4.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 6.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 4.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 7.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 7.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 5.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 5.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 9.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.020000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.127000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 9.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 7.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 6.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 7.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 7.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 6.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 7.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 2.010000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 2.280000e+09
                                           us-gaap:Revenues 2025-09-30                                                                                                                                                                   1.577600e+10
                                           us-gaap:Revenues 2024-09-30                                                                                                                                                                   1.446000e+10
                                           us-gaap:Revenues 2025-09-30                                                                                                                                                                   4.454200e+10
                                           us-gaap:Revenues 2024-09-30                                                                                                                                                                   4.123200e+10
                                           us-gaap:Revenues 2025-09-30                                                                                                                                                                   1.577600e+10
                                           us-gaap:Revenues 2024-09-30                                                                                                                                                                   1.446000e+10
                                           us-gaap:Revenues 2025-09-30                                                                                                                                                                   4.454200e+10
                                           us-gaap:Revenues 2024-09-30                                                                                                                                                                   4.123200e+10
                                us-gaap:OperatingIncomeLoss 2025-09-30                                                                                                                                                                   1.904000e+09
                                us-gaap:OperatingIncomeLoss 2024-09-30                                                                                                                                                                   3.831000e+09
                                us-gaap:OperatingIncomeLoss 2025-09-30                                                                                                                                                                   1.053100e+10
                                us-gaap:OperatingIncomeLoss 2024-09-30                                                                                                                                                                   1.062700e+10